The Canada Dry-Eye Medication market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
It is estimated that around thirty percent of Canadians experience ocular symptoms associated with dry eye. These symptoms include stinging or burning eyes, scratchiness, pain, or redness. Strangely enough one of the symptoms of dry eye may be an excessive production of tears such that a patient with dry eye may have tears rolling down their face. According to a new survey commissioned by Alcon Canada, Canadians have self-reported spending an average of nearly 11 hours per day looking at screens and it could be affecting the quality of their vision, with up to 25 percent of Canadians suffering from dry eye. The survey finds that 85 percent of Canadians have experienced at least one symptom of dry eye. This can include eye fatigue (46%), watery eyes (42%), sensitivity to light (38%), blurred vision (34%), eye redness (33%), and difficulty with night-time driving (27%).
Prevalence of the aging population and the popularization of electronic products such as mobile phones and tablets, which have led to changes in eye use habits, it is expected that patients with dry eyes will still show a growth trend in the future. A rising number of contact lens users, increase in disposable income, increase in the number of treatment options and an increased number of allergies will boost the market growth. Going forward, rising laser surgeries, busy lifestyles, the increasing burden of diabetes, an increase in the prevalence of dry eye disease, the promising pipeline for dry eye disease, and the side effects of other medications will drive growth. Factors that could hinder the growth of the dry eye medication market in the future include long and costly drug approvals, stringent rules and regulations, and disruption in the supply chain of drugs related to dry eyes due to the impact of covid-19.